News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Protector post# 141916

Monday, 09/23/2013 7:48:42 PM

Monday, September 23, 2013 7:48:42 PM

Post# of 347009
If Calico would be more of a spinoff from Genentech, I doubt the Roche family would like something like that... as it may force some from Genentech over to Calico under Dr. Arthur Levinson and since I'm sure ex-CEO Dr. Arhtur Levinson likes what Dr. Garnick has been able to accomplish as well --- I could only imagine that partnership. As for the Apple connection, I would only expect many Peregrine Apps and a PR campaign that only Bavi would deserve.... and ok, have to retreat a little bit over what could happen.....

Moreover, Google is tapping a heavyweight biotech pioneer to lead the initiative. Dr. Arthur Levinson is a solid choice for the job, given that he’s the former chief executive at Genentech. He plans to remain the chairman of the board of directors of both Genentech and Apple, a position he assumed after Steve Jobs died in 2011.

http://venturebeat.com/2013/09/20/calico-how-googles-stab-at-the-fountain-of-youth-could-transform-health-care/


------------------------------------------------------------

Genentech April 12, 2001

"As we celebrate Genentech and biotech's first 25 years with our products having touched the lives of over one million people, we continue to move projects through our pipeline to treat cancer, heart disease and other significant unmet medical needs while providing strong financial returns for our stockholders," said Arthur D. Levinson, Ph.D., Genentech's chairman and chief executive officer.

Corporate Business Events

Announced the appointment of Richard H. Scheller as senior vice president, Research and the promotions of Robert Garnick as senior vice president, Regulatory, Quality and Compliance; Kim Popovits as senior vice president, Marketing and Sales; and John Whiting as vice president in addition to his role as controller and chief accounting officer.

http://www.gene.com/media/press-releases/4655/2001-04-12/genentech-reports-38-percent-increase-in
-----------------------------------------------------------------



"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y